Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)

• Company Description    Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada. Number of Employees: 129

• Price / Volume Information    Yesterday's Closing Price: $1.84 Daily Weekly Monthly 20 Day Moving Average: 198,576 shares Shares Outstanding: 42.96 (millions) Market Capitalization: $79.04 (millions) Beta: 1.06 52 Week High: $4.07 52 Week Low: $0.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -1.63% 12 Week 19.48% 11.14% Year To Date 40.46% 20.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7171 Frederick-Banting Building 2 Suite 270 - St-Laurent,A8 H4S 1Z9 CAN ph: 857-412-7018 fax: - investor@reparerx.com http://www.reparerx.com

• General Corporate Information    Officers Lloyd M. Segal - President and Chief Executive Officer Thomas Civik - Chairman Steve Forte - Executive Vice President; Chief Financial Officer David Bonita - Director Samarth Kulkarni - Director Peer Information Repare Therapeutics Inc. (CORR.) Repare Therapeutics Inc. (RSPI) Repare Therapeutics Inc. (CGXP) Repare Therapeutics Inc. (BGEN) Repare Therapeutics Inc. (GTBP) Repare Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 760273102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 42.96 Most Recent Split Date: (:1) Beta: 1.06 Market Capitalization: $79.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.71 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 52.44% vs. Previous Quarter: 45.07% Sales Growth vs. Year Ago Period: -76.70% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -78.25 03/31/25 - -78.12 ROA 09/30/25 - - 06/30/25 - -66.85 03/31/25 - -67.11 Current Ratio 09/30/25 - - 06/30/25 - 6.30 03/31/25 - 7.42 Quick Ratio 09/30/25 - - 06/30/25 - 6.30 03/31/25 - 7.42 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -43,504.40 03/31/25 - -11,809.23 Book Value 09/30/25 - - 06/30/25 - 2.57 03/31/25 - 2.92 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©